Clinical Trial Phases
From pre-clinical development through Phase 1, 2, 3, and 4 post-market surveillance
Overview
Vaccine clinical trials are conducted in a structured sequence of phases, each designed to answer specific questions about safety, immune response, and effectiveness. No vaccine can be approved for public use without completing this process. Each phase must demonstrate acceptable safety before the next phase begins.
The full clinical trial process typically takes 10–15 years for a conventional vaccine. Accelerated timelines (such as during COVID-19) used parallel development and pre-investment — but did not skip any phase.
Pre-Clinical Phase
Before any human testing, vaccines are tested extensively in laboratory and animal studies:
Laboratory Studies
Vaccine candidates are tested in cell cultures to assess whether they produce the intended immune response. Dozens of candidates may be tested; most fail at this stage.
Animal Studies
Promising candidates are tested in animals (typically mice, then primates) to assess immune response, identify appropriate dosing, and screen for early safety signals.
IND Application
If pre-clinical results are promising, the developer submits an Investigational New Drug (IND) application to the FDA. Approval of the IND allows human trials to begin.
Safety & Dosing
Participants
20–100 healthy adults
Duration
1–2 years
Primary Goals
- Confirm the vaccine is safe enough to proceed
- Identify the immune response produced
- Determine appropriate dosing levels
- Identify common short-term side effects
Phase 1 trials are not designed to test effectiveness — the group is too small.
Expanded Safety & Immunogenicity
Participants
Hundreds — diverse age groups
Duration
2–3 years
Primary Goals
- Further assess safety across a broader population
- Confirm and characterise the immune response (immunogenicity)
- Optimise dosing schedule (number of doses, timing)
- Identify less common side effects
Phase 2 results determine whether the vaccine produces a strong enough immune response to justify the large Phase 3 trial.
Efficacy & Large-Scale Safety
Participants
Thousands to tens of thousands
Duration
2–4 years
Primary Goals
- Determine whether the vaccine actually prevents disease (efficacy) compared to placebo
- Detect less common adverse events that Phase 1/2 were too small to identify
- Confirm safety across diverse populations (age, ethnicity, health status)
Phase 3 trials are the primary basis for regulatory approval. COVID-19 Phase 3 trials enrolled 30,000–44,000 participants.
Post-Market Surveillance
Phase 4 begins after regulatory approval and continues indefinitely. It is sometimes called post-market surveillance.
VAERS
Passive surveillance — anyone can report adverse events. Signal detection tool. Managed by CDC and FDA.
VSD
Active surveillance — monitors 12 million covered lives using electronic health records. Can calculate true incidence rates.
BEST
FDA's active surveillance system. Near real-time monitoring of both safety and effectiveness in tens of millions of people.
Phase 4 Clinical Trials
Some manufacturers conduct formal Phase 4 trials as a condition of approval — particularly for accelerated approvals or when specific populations require further study.
Sources & Citations
- FDA. "Vaccine Development — 101." fda.gov, 2023.
- CDC. "Vaccine Testing and the Approval Process." cdc.gov/vaccines, 2023.
- WHO. "How are vaccines developed?" who.int, 2023.
- Plotkin S et al. Vaccines. 7th edition. Elsevier, 2018.